Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNK Stock Price Chart Interactive Chart >
MNK Price/Volume Stats
| Current price | $7.66 | 52-week high | $31.00 |
| Prev. close | $7.91 | 52-week low | $0.10 |
| Day low | $7.59 | Volume | 5,300 |
| Day high | $7.98 | Avg. volume | 47,649 |
| 50-day MA | $8.06 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 100.89M |
Mallinckrodt plc Ordinary Shares (MNK) Company Bio
Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.
Latest MNK News From Around the Web
Below are the latest news stories about MALLINCKRODT PLC that investors may wish to consider to help them evaluate MNK as an investment opportunity.
McKinsey Consulted VA While Advising Opioid Makers to Target Agency for SalesSince at least 2009, McKinsey has been a consultant to the U.S. Department of Veterans Affairs. During part of that time, the consulting giant also advised some of the world’s biggest opioid producers to target the federal agency for sales of their products, according to newly released documents. |
Mallinckrodt plc (AMEX:MNK) Q4 2022 Earnings Call TranscriptMallinckrodt plc (AMEX:MNK) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good day, and thank you for standing by. Welcome to the Mallinckrodt Q4 2022 Earnings Announcement. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. please be advised that today’s conference is […] |
Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Japan's National Health Insurance (NHI) system has approved reimbursement for the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or -intolerant chronic graft versus host disease (cGvHD). |
Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 GuidanceMallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022. |
Mallinckrodt to Present at Cowen's 43rd Annual Health Care ConferenceMallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen's 43rd Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2023 at 2:50 p.m. Eastern Time. |
MNK Price Returns
| 1-mo | -0.51% |
| 3-mo | -11.03% |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -1.16% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Continue Researching MNK
Want to see what other sources are saying about Mallinckrodt plc's financials and stock price? Try the links below:Mallinckrodt plc (MNK) Stock Price | Nasdaq
Mallinckrodt plc (MNK) Stock Quote, History and News - Yahoo Finance
Mallinckrodt plc (MNK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...